BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16

• Press Releases

  U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

  July 13, 2026

   · 

  19 min read
• Press Releases

  AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs

  July 13, 2026

   · 

  5 min read
• 

  Opinion

  The FDA needs a patient-first vision—and adcomms with patients at the table

  FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.

  July 13, 2026

   · 

  4 min read

   · 

  Houman David Hemmati
• Press Releases

  Sanofi: Information concerning the total number of voting rights and shares - June 2026

  July 13, 2026

   · 

  1 min read
• Press Releases

  Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

  July 13, 2026

   · 

  5 min read
• Press Releases

  FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

  July 13, 2026

   · 

  19 min read
• Press Releases

  Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 10, 2026

  July 13, 2026

   · 

  1 min read
• Press Releases

  Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 10, 2026

  July 13, 2026

   · 

  2 min read
• Press Releases

  Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 10, 2026

  July 13, 2026

   · 

  2 min read
• Press Releases

  VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister

  July 13, 2026

   · 

  4 min read